Introduction
Used as an over-the-counter drug to enhance energy and memory, the standardized Ginkgo biloba leaf extract, or EGb 761® (EGb 761), is one of the most effective and commonly used nutraceuticals in the market. In Europe, EGb 761 is prescribed for multiple problems related to mental health and overall wellbeing. Several studies have shown EGb 761 to have neuroprotective properties, but the mechanism(s) underlying this effect has not been fully studied and requires further evaluation. Previously, our group has shown that heme oxygenase 1 (HO1) is essential for EGb 761 neuroprotection against ischemia in rodent models of transient middle cerebral artery (MCA) occlusion (tMCAO) (Saleem et al., 2008) and permanent distal MCA occlusion (pMCAO) (Shah et al., 2011) . Furthermore, EGb 761 was shown to upregulate endothelial nitric oxide synthase and vascular endothelial growth factor in ipsilateral cortices of mice that have undergone experimental stroke, suggesting the possible contribution of these vasodilators (Shah et al., 2011) .
Ischemic stroke is a leading cause of disability in the United States and worldwide (Elkins and Johnston, 2003) . Insufficient oxygen and nutrients during cerebral ischemia triggers multiple biochemical cascades that result in axonal injury, breakdown of neuronal cytoskeleton, and neuronal degeneration and death (Won et al., 2002) . Collapsin response mediator protein 2 (CRMP2) is crucial for axon outgrowth and determines the fate of axons and dendrites. It was originally identified as a signaling molecule required for growth cone collapse of dorsal root ganglion neurons in response to a repulsive guidance cue (Goshima et al., 1995) . Overexpression of CRMP2 induces the formation of multiple axons, whereas knockdown of CRMP2 suppresses axon formation (Inagaki et al., 2001; Suzuki et al., 2003; Yoshimura et al., 2005) , indicating that CRMP2 has a positive effect on axonal extension and plays a key role in dendrite specification and axon regeneration. CRMP2 colocalizes with F-actin in the growth cones of different types of neurons (Goshima et al., 1995; Minturn et al., 1995; Yuasa-Kawada et al., 2003) and also binds to actin, but its binding is not affected by phosphorylation (Arimura et al., 2005) .
With the backdrop of failed neuroprotective agents in phase III clinical trials, there is an urgent prerequisite to develop neuroprotective 
